

43. Soares A, Cunha R, Rodrigues F, et al. Smooth muscle autoantibodies with F-actin specificity. *Autoimmun Rev* 2009; 8: 713–716.
44. Chan Y, Tong HQ, Beggs AH, et al. Human skeletal musclespecific alpha-actinin-2 and -3 isoforms form homodimers and heterodimers in vitro and in vivo. *Biochem Biophys Res Commun* 1998; 248: 134–139.
45. Guéguen P, Dalekos G, Nousbaum JB, et al. Double reactivity against actin and alpha-actinin defines a severe form of autoimmune hepatitis type 1. *J Clin Immunol* 2006; 26: 495–505.
46. Ballot E, Homberg JC, Johanet C. Antibodies to soluble liver antigen: an additional marker in type 1 auto-immune hepatitis. *J Hepatol* 2000; 33: 208–215.
47. Czaja AJ, Donaldson PT, Lohse AW. Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis. *Am J Gastroenterol* 2002; 97: 413–419.
48. Czaja AJ, Carpenter HA, Manns MP. Antibodies to soluble liver antigen, P450IID6, and mitochondrial complexes in chronic hepatitis. *Gastroenterology* 1993; 105: 1522–1528.
49. Efe C, Ozaslan E, Wahlin S, et al. Antibodies to soluble liver antigen in patients with various liver diseases: a multicentre study. *Liver Int* 2013; 33: 190–196.
50. Volkmann M, Luthle D, Zentgraf H, et al. SLA/LP/trNP(Ser)Sec antigen in autoimmune hepatitis: identification of the native protein in human hepatic cell extract. *J Autoimmun* 2010; 34: 59–65.
51. Wies I, Brunner S, Henninger J, et al. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. *Lancet* 2000; 355: 1510–1515.
52. Terjung B, Söhne J, Lechtenberg B, et al. p-ANCA in autoimmune liver disorders recognise human beta-tubulin isotype 5 and cross-react with microbial protein FtsZ. *Gut* 2010; 59: 808–816.
53. Terjung B, Spengler U, Sauerbruch T, et al. "Atypical p-ANCA" in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines. *Gastroenterology* 2000; 119: 310–322.
54. Roozendaal C, de Jong MA, van den Berg AP, et al. Clinical significance of anti-neutrophil cytoplasmic antibodies (ANCA) in autoimmune liver diseases. *J Hepatol* 2000; 32: 734–741.
55. Czaja AJ, Pfeifer KD, Decker RH et al. Frequency and significance of antibodies to asialoglycoprotein receptor in type 1 autoimmune hepatitis. *Dig Dis Sci* 1996; 41: 1733–1740.
56. Yoshioka M, Mizuno M, Morisue Y, et al. Anti-asialoglycoprotein receptor autoantibodies, detected by a capture-immunoassay, are associated with autoimmune liver diseases. *Acta Med Okayama* 2002; 56: 99–105.
57. Johnson PJ, McFarlane IG, McFarlane BM, et al. Autoimmune features in patients with idiopathic chronic active hepatitis who are seronegative for conventional auto-antibodies. *J Gastroenterol Hepatol* 1990; 5: 244–251.
58. McFarlane IG, Hegarty JE, McSorley CG, et al. Antibodies to liver-specific protein predict outcome of treatment withdrawal in autoimmune chronic active hepatitis. *Lancet* 1984; 2: 954–956.
59. Roggenbuck D, Mytilinaiou MG, Lapin SV, et al. Asialoglycoprotein receptor (ASGPR): a peculiar target of liverspecific autoimmunity. *Auto Immun Highlights* 2012; 3: 119–125.
60. Martini E, Abuaf N, Cavalli F, et al. Antibody to liver cytosol (anti-LC1) in patients with autoimmune chronic active hepatitis type 2. *Hepatology*. 1988; 8: 1662–1666.
61. Abuaf N, Johanet C, Chretien P, et al. Characterization of the liver cytosol antigen type 1 reacting with autoantibodies in chronic active hepatitis. *Hepatology* 1992; 16: 892–898.
62. Czaja AJ, Shums Z, Norman GL. Nonstandard antibodies as prognostic markers in autoimmune hepatitis. *Autoimmunity* 2004; 37: 195–201.
63. Renous R, Lapierre P, Djilali-Saiah I, et al. Characterization of the antigenicity of the formiminotransferasecyclodeaminase in type 2 autoimmune hepatitis. *Exp Cell Res* 2004; 292: 332–341.
64. Béland K, Lapierre P, Marceau G, et al. Anti-LC1 autoantibodies in patients with chronic hepatitis C virus infection. *J Autoimmun* 2004; 22: 159–166.
65. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. *J Hepatol* 1999; 31: 929–938.
66. Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. *Hepatology* 2008; 48: 169–176.
67. Czaja AJ. Performance parameters of the diagnostic scoring systems for autoimmune hepatitis. *Hepatology* 2008; 48: 1540–1548.
68. Czaja AJ. Comparability of probable and definite autoimmune hepatitis by international diagnostic scoring criteria. *Gastroenterology* 2011; 140: 1472–1480.
69. Lamers MMH, van Oijen MGH, Pronk M, et al. Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials. *J Hepatol* 2010; 53: 191–198.
70. EASL Clinical Practice Guidelines: autoimmune hepatitis. *J Hepatol* 2015; 63: 971–1004.
71. Manns MP, Woynarowski M, Kreisel W, et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. *Gastroenterology* 2010; 139: 1198–1206.
72. Liberal R, de Boer YS, Andrade RJ, et al. Expert clinical management of autoimmune hepatitis in the real world. *Aliment Pharmacol Ther* 2017; 45: 723–732.
73. Peiseler M, Liebscher T, Sebode M, et al. Efficacy and Limitations of Budesonide as a Second-Line Treatment for Patients With Autoimmune Hepatitis. *Clin Gastroenterol Hepatol* 2018; 16: 260–267.
74. Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. *Am J Gastroenterol* 1996; 91: 423–433.
75. Akbari M, Shah S, Velayati FS, et al. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. *Inflamm Bowel Dis* 2013; 19: 15–22.
76. Casanova MJ, Chaparro M, Domènech E, et al. Safety of thiopurines and anti-TNF-alpha drugs during pregnancy in patients with inflammatory bowel disease. *Am J Gastroenterol* 2013; 108: 433–440.
77. van Gerven NMF, Verwer BJ, Witte BJ, et al. Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission. *J Hepatol* 2013; 58: 141–147.
78. Soloway RD, Summerskill WH, Baggenstoss AH, et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. *Gastroenterology* 1972; 63: 820–833.